Firefly has announced the discovery of new brain wave biomarkers that may help identify ADHD subtypes, addressing a long-standing gap in psychiatric diagnostics. Over 22 million Americans are diagnosed with ADHD, yet an objective biological marker for distinguishing between its three distinct subtypes has remained elusive until now.
Firefly’s AI-powered EEG/ERP technology may help identify which ADHD subtype a patient has, potentially complementing subjective symptom checklists with neural signal-based precision. This advancement could significantly change clinical practice by helping clinicians determine the most appropriate treatment type, inform dosage decisions, and potentially monitor whether an intervention is working.
The breakthrough represents progress toward Firefly’s broader mission to build the world’s first EEG/ERP brain foundation model. The company is training this model on a growing repository of over 191,000 brain scans. Firefly’s methodology is supported by prior peer-reviewed research, including a study published in Frontiers in Psychiatry that demonstrated the diagnostic utility of EEG-based brain activity flow pattern analysis in ADHD patients.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.benzinga.com/pressreleases/26/03/g51237072/firefly-announces-discovery-of-new-brain-wave-biomarkers-for-differential-diagnosis-of-adhd